Literature DB >> 8717052

A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12.

D W Johnson1, J N Berg, C J Gallione, K A McAllister, J P Warner, E A Helmbold, D S Markel, C E Jackson, M E Porteous, D A Marchuk.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT) or Osler-Rendu-Weber (ORW) disease is an autosomal dominant vascular dysplasia. Initial linkage studies identified an ORW gene localized to 9q33-q34 but with some families clearly excluding this region. A probable correlation in clinical phenotype between the 9q3-linked families and unlinked families was described with a significantly lower incidence of pulmonary arteriovenous malformations observed in the unlinked families. In this study we examined four unrelated ORW families for which linkage to chromosome 9q33-q34 has been previously excluded. Linkage was established for all four families to markers on chromosome 12, with a combined maximum lod score of 10.77 (theta = 0.04) with D12S339. Mapping of crossovers using haplotype analysis indicated that the candidate region lies in an 11-CM interval between D12S345 and D12S339, in the pericentromeric region of chromosome 12. A map location for a second ORW locus is thus established that exhibits a significantly reduced incidence of pulmonary involvement.

Entities:  

Mesh:

Year:  1995        PMID: 8717052     DOI: 10.1101/gr.5.1.21

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.043


  37 in total

Review 1.  Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms.

Authors:  C L Shovlin; M Letarte
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement.

Authors:  B S Jacobson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 3.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

4.  Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1.

Authors:  A Bourdeau; U Cymerman; M E Paquet; W Meschino; W C McKinnon; A E Guttmacher; L Becker; M Letarte
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

5.  Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin?

Authors:  J N Berg; A E Guttmacher; D A Marchuk; M E Porteous
Journal:  J Med Genet       Date:  1996-03       Impact factor: 6.318

Review 6.  Developmental and pathological angiogenesis in the central nervous system.

Authors:  Mario Vallon; Junlei Chang; Haijing Zhang; Calvin J Kuo
Journal:  Cell Mol Life Sci       Date:  2014-04-24       Impact factor: 9.261

7.  Angiographic and clinical characteristics of patients with cerebral arteriovenous malformations associated with hereditary hemorrhagic telangiectasia.

Authors:  S Matsubara; J L Mandzia; K ter Brugge; R A Willinsky; M E Faughnan; J L Manzia
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

8.  Visceral manifestations in hereditary haemorrhagic telangiectasia type 2.

Authors:  S A Abdalla; U W Geisthoff; D Bonneau; H Plauchu; J McDonald; S Kennedy; M E Faughnan; M Letarte
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

9.  Hereditary hemorrhagic telangiectasia in Japanese patients.

Authors:  Masaki Komiyama; Tomoya Ishiguro; Osamu Yamada; Hiroko Morisaki; Takayuki Morisaki
Journal:  J Hum Genet       Date:  2013-11-07       Impact factor: 3.172

10.  Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative.

Authors:  N Pece; S Vera; U Cymerman; R I White; J L Wrana; M Letarte
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.